发明名称 |
Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD) |
摘要 |
Macromolecule intracellular transduction technology based on improved cell-permeable Parkin recombinant protein (iCP-Parkin) has been developed as a protein-based anti-neurodegenerative agent for efficient BBB-penetration to effectively deliver the recombinant protein into the brain. Parkin protein, a dopaminergic neuronal cell death inhibitor, has been fused with a newly developed advanced macromolecule transduction domain (aMTD) and solubilization domain (SD) to increase the solubility/yield and cell-/tissue-permeability of the recombinant protein. In addition, our newly developed aMTD/SD-fused recombinant iCP-Parkin protein has shown BBB-permeability. Both in vitro and in vivo, our iCP-Parkin recombinant protein improved motor skills, a typical phenotype of Parkinson's disease, by increasing dopamine level in the brain by suppressing apoptosis of dopaminergic neuron cells. In conclusion, iCP-Parkin could be applicable in clinical studies as a protein-based anti-neurodegenerative agent to treat Parkinson's disease by protecting dopaminergic neuron cells and regulating the secretion of dopamine. |
申请公布号 |
US2017029798(A1) |
申请公布日期 |
2017.02.02 |
申请号 |
US201514809279 |
申请日期 |
2015.07.27 |
申请人 |
JO DAEWOONG;Cellivery Therapeutics, Inc. |
发明人 |
JO Daewoong;HA EUNSIN;LEE JIEUN;JEON JEONGMIN;LEE KWANGJAE |
分类号 |
C12N9/00;G01N33/573 |
主分类号 |
C12N9/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for development of the new hydrophobic cell-penetrating peptides (CPPs), namely advanced macromolecule transduction domains (aMTDs) |
地址 |
Brentwood TN US |